José Antonio Allué, PhD
Head of Mass Spectrometry at Araclon Biotech-Grifols

José Antonio Allué, PhD, is Head of Mass Spectrometry at Araclon Biotech-Grifols. His work focuses on the study of biomarkers related to Alzheimer’s disease, including the use of plasma Aβ42/Aβ40 to identify early amyloid changes in individuals with subjective cognitive decline.

Participació
14th May, 2026
Plasma Aβ42/Aβ40 Identifies Early Amyloid Changes in PET Negative Individuals with Subjective Cognitive Decline